Vitrolife AB, headquartered in Sweden, is a leading provider of products and systems for in-vitro fertilization (IVF) and cell therapy. The company develops, manufactures, and distributes innovative solutions to improve fertility and support stem cell therapies. Vitrolife AB supports clinics worldwide with high-quality IVF kits, culture media, and cell culture products, driving advancements in reproductive medicine and regenerative therapies.
Date confirmed from the iCal calendar the company offers on its IR page.
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Vitrolife AB is scheduled to report its next quarterly earnings on 10/22/2026. Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Vitrolife AB last reported quarterly earnings on 7/16/2026 (Q2 2026). Earnings per share (EPS) came in at 0.96 SEK.
Vitrolife AB has beaten analyst EPS estimates in 2 of its last 3 evaluated quarters (beat rate: 66.7%).
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
Basis: 3 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.